Research & Education
CURE Expert Connections
CURE Speaking Out
Ovarian Cancer Heroes
Email Sign Up
To start your customized experience click the start button
Customize your homepage by selecting specific cancer types.
See all >
Acute Myeloid Leukemia
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
Mantle Cell Lymphoma
Metastatic Breast Cancer
Side Effect Management
Small Lymphocytic Lymphoma (SLL)
Advocacy & Research
Share Your Story
Newsletter Sign Up
See all >
EDUCATED PATIENT SUMMIT: Lung Cancer
AWARD PROGRAM: Lung Cancer Heroes
Ovarian Cancer Heroes
Bone Health Champions
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Squamous Cell Carcinoma Resource Guide
FDA Approves Tecentriq in Combination with Cotellic and Zelboraf for Patients with Advanced Skin Cancer
The Food and Drug Administration has approved Tecentriq in combination with Cotellic and Zelboraf for the treatment of patients with BRAF V600 mutation-positive advanced melanoma.
The Future of Melanoma Treatment May Be Complex, But 'Where There's a Will, There's a Way'
Research in the melanoma space is finding itself facing complex challenges in implementing CAR-T cell therapy, but according to one expert these challenges are not insurmountable.
Investigating a Health Gap in Skin Cancer
CURE Community Vlog: One Patient's Journey With Merkel Cell Carcinoma
Kristie L. Kahl
“You have to speak up. What you don’t say is the most predictive of the care you don’t get.”
Speaking Out: Taking Action Against Skin Cancer
By Beth Fand Incollingo and Kristie L. Kahl
Patients can pick from a growing array of treatments, from same-day- results surgery to game-changing immunotherapy, to fight the most common type of cancer.
FDA Approves Keytruda for Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma
The Food and Drug Administration approved Keytruda to treat patients with recurrent or metastatic cutaneous squamous cell carcinoma that cannot be treated with surgery or radiation.
Tafinlar and Mekinist Improve Long-Term Survival in Patients with BRAF Positive Melanoma
“The relapse-free survival curves for both treatment arms appear to be reaching a plateau, which is a good sign if we are talking about cure,” said lead study author Dr. Axel Hauschild.
The Future of CSCC Management
Key opinion leaders close the discussion by considering the future of cutaneous squamous cell carcinoma (CSCC) and promising emerging regimens.
Multidisciplinary Management of CSCC
Experts in skin-care management discuss the role of the multidisciplinary team to provide patients with the best treatment strategy.
Immunotherapy in Patients Receiving Organ Transplantation
A discussion of the possibility of managing organ transplant populations with immunotherapy.
Not a member?
Sign up now!
Continue without login